The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Winrevair (sotatercept-csrk), an approved injection therapy for adults with pulmonary arterial hypertension (PAH) marketed by Merck. The most notable change in this update is the addition of a contraindication (a…
News
A national database study found substantial variation in how clinicians manage people hospitalized with pulmonary arterial hypertension (PAH) who presented with shock, a life-threatening lack of blood flow to the body’s organs. Researchers identified 25 different initial treatment strategies involving vasoactive medications, drugs that adjust blood pressure and heart…
Measurements that look at the interplay between the pulmonary arteries and the heart may help predict the likelihood of survival among people with all forms of pulmonary hypertension (PH), according to a study. These measurements were able to predict mortality risk even in mild PH, whereas conventional disease severity…
Mosliciguat, an inhaled treatment being developed by Pulmovant, was well tolerated and more effective than a placebo at improving blood flow through the lungs of adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD), supporting its move into Phase 3 clinical testing, which is already underway. That’s…
The PAH Initiative will once again host a live broadcast event — this time focusing on how oxygen therapy can become part of the care plan for people living with pulmonary arterial hypertension (PAH) — and registration for the free hour-long program is now open. The event, called…
A noninvasive measure of heart and blood vessel function called the TAPSE/sPAP ratio can help doctors objectively assess the severity of day-to-day symptoms in people with pulmonary arterial hypertension (PAH), according to a new study. Researchers found that lower ratio values closely mirror greater physical limitations in patients, providing…
A measurement taken by heart MRI was linked to several invasive measures used to assess pulmonary hypertension (PH), a new study shows. The measurement, known as T2RV/LV, “represents a highly promising non-invasive biomarker for risk stratification, disease monitoring, and assessment of treatment response in PH,” the researchers wrote. They…
Two blood-based biomarkers — GDF-15 and NT-proBNP — most accurately distinguished adults with pulmonary hypertension (PH) from healthy individuals in a study that compared five biomarkers. The retrospective study, conducted at Beijing Anzhen Hospital in China, evaluated traditional and newer biomarkers across the four main clinical subtypes of…
Adults with pulmonary arterial hypertension (PAH) taking Remodulin (treprostinil) or Veletri (epoprostenol) safely switched to Uptravi (selexipag) during carefully monitored hospital stays using a rapid dose-titration plan, a new study reports. The findings may help guide clinicians who are transitioning appropriate PAH patients from infusion therapy…
A measure derived from heart and lung imaging data can predict the long-term risk of death for people with newly diagnosed pulmonary arterial hypertension (PAH), a study found. The measure, called FAC/PASP, was better at predicting long-term death rates than a more established measure, TAPSE/PASP, the study showed. Both measures are…
Chronic kidney disease (CKD) is common among people newly diagnosed with pulmonary hypertension (PH), and patients face an increased risk of developing CKD — marked by worsening kidney function over time — as the condition progresses, according to a new study. The researchers found that certain blood flow measures,…
People with severe pulmonary arterial hypertension (PAH) who respond well to early treatment with prostacyclin infusions may be able to reduce or stop the treatment, a study suggested. In a long-term analysis of 101 patients, about one in five achieved enough improvement in heart and lung blood flow measurements…
